ACTIVE_NOT_RECRUITING

Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The overall goal of this study is to promote awareness of Familial Hypercholesterolemia (FH). The investigators aim to enroll patients with suspected FH into the study and will randomize them to receive usual care or motivational interview. Primary study outcomes include knowledge of FH, as well as clinical and patient-reported outcomes. This study aims to promote optimal disease management and improve outcomes of FH patients.

Official Title

Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

Quick Facts

Study Start:2022-02-15
Study Completion:2026-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT05238519

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:2 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 2-75 years
  2. * patients with existing clinical diagnosis or suspected FH
  3. * known genetic mutation of FH
  4. * patients with an initial (pretreatment) LDL level \>190 mg/dL or total cholesterol \>300 mg/dL (age \>19 years) or LDL-c \> 160mg/dL or total cholesterol \>260 mg/dL in children age 2-19 years
  5. * patients currently taking a lipid-lowering medication and have an LDL \>124 mg/dL or total cholesterol \>195 mg/dL
  6. * capable of providing informed consent
  7. * Patients should reside in Minnesota, Wisconsin or North Dakota.
  1. * Lack of research authorization
  2. * unable to provide informed consent (including non-English speaking individuals)
  3. * known medical condition other than FH that is thought to contribute to hyperlipidemia (i.e., untreated hypothyroidism, nephrotic syndrome, cholestasis hypopituitarism)
  4. * Pregnant women and prisoners will also be excluded.

Contacts and Locations

Study Locations (Sites)

Aspirus St. Luke's Hospital
Duluth, Minnesota, 55805
United States
Essentia Health
Duluth, Minnesota, 55805
United States

Collaborators and Investigators

Sponsor: Essentia Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-02-15
Study Completion Date2026-06

Study Record Updates

Study Start Date2022-02-15
Study Completion Date2026-06

Terms related to this study

Keywords Provided by Researchers

  • cholesterol
  • motivational interview
  • survey
  • cascade screening

Additional Relevant MeSH Terms

  • Familial Hypercholesterolemia
  • Cholesterol, Elevated
  • Genetic Disease